IMMX - Immix Biopharma, Inc. Common Stock Stock Price, Fair Value and News

2.30USD+0.17 (+7.98%)Market Closed

Market Summary

USD2.30+0.17

Market Closed

7.98%

IMMX Stock Price

View Fullscreen

IMMX RSI Chart

IMMX Valuation

Market Cap

61.2M

Price/Earnings (Trailing)

-3.96

EV/EBITDA

-2.81

Price/Free Cashflow

-5.36

MarketCap/EBT

-3.93

IMMX Price/Earnings (Trailing)

IMMX Profitability

Return on Equity

-94.15%

Return on Assets

-77.52%

Free Cashflow Yield

-18.65%

IMMX Fundamentals

IMMX Earnings

Earnings (TTM)

-15.4M

Earnings Growth (Yr)

-33.41%

Earnings Growth (Qtr)

-18.42%

Breaking Down IMMX Revenue

Last 7 days

-9.7%

Last 30 days

-29.5%

Last 90 days

-50.4%

Trailing 12 Months

29.6%

How does IMMX drawdown profile look like?

IMMX Financial Health

Current Ratio

5.32

IMMX Investor Care

Shares Dilution (1Y)

89.24%

Diluted EPS (TTM)

-0.98

Tracking the Latest Insider Buys and Sells of Immix Biopharma, Inc. Common Stock

Filter Transactions

Datesorted ascending	Name	Buy/Sell	$ Value	Avg. Price	# Shares	Title
Dec 11, 2023	hsu jason	bought	144,894	4.674	31,000	-
Dec 08, 2023	hsu jason	bought	122,025	4.881	25,000	-
Sep 15, 2023	hsu jason	bought	17,396	2.4852	7,000	-
Sep 14, 2023	hsu jason	bought	25,772	2.5772	10,000	-
Sep 14, 2023	ng carey	bought	25,760	2.576	10,000	-
Sep 12, 2023	hsu jason	bought	84,864	2.8288	30,000	-
Sep 12, 2023	adams helen c.	bought	38,491	2.9609	13,000	-
Sep 11, 2023	hsu jason	bought	72,280	2.8912	25,000	-
Sep 08, 2023	hsu jason	bought	25,317	2.5317	10,000	-
Sep 07, 2023	buchan melissa jane	bought	49,226	2.4613	20,000	-

Which funds bought or sold IMMX recently?

View All Details

Datesorted ascending	Fund Name	Type	% Chg	$ Change	$ Held	% Portfolio
Apr 15, 2024	OLD NATIONAL BANCORP /IN/	unchanged	-	-38,500	30,700	-%
Mar 11, 2024	VANGUARD GROUP INC	added	51.02	746,716	1,109,950	-%
Feb 29, 2024	Tortoise Investment Management, LLC	unchanged	-	4,550	8,996	-%
Feb 15, 2024	JANE STREET GROUP, LLC	new	-	103,261	103,261	-%
Feb 14, 2024	STATE STREET CORP	unchanged	-	150,360	297,283	-%
Feb 14, 2024	BANK OF AMERICA CORP /DE/	new	-	11,031	11,031	-%
Feb 14, 2024	EAM Investors, LLC	new	-	710,414	710,414	0.13%
Feb 14, 2024	SUSQUEHANNA INTERNATIONAL GROUP, LLP	new	-	99,309	99,309	-%
Feb 14, 2024	Royal Bank of Canada	new	-	-	-	-%
Feb 13, 2024	RENAISSANCE TECHNOLOGIES LLC	new	-	224,000	224,000	-%

Are Funds Buying or Selling IMMX?

Are funds buying IMMX calls or puts?

Calls

Puts

No. of funds holding Calls - Puts

Net Call Options

No. of funds that own IMMX

No. of Funds

Unveiling Immix Biopharma, Inc. Common Stock's Major ShareHolders

Date Filed	Name of Filer	Percent of Class	No. of Shares	Form Type
Feb 07, 2024	hirschman orin	5.8%	1,455,000	SC 13G
Aug 30, 2023	gkcc, llc	19.99%	3,255,734	SC 13D

Recent SEC filings of Immix Biopharma, Inc. Common Stock

View All Filings

Date Filed	Form Type	Document
Mar 29, 2024	10-K	Annual Report
Feb 20, 2024	S-8	Employee Benefits Plan
Feb 07, 2024	SC 13G	Major Ownership Report
Feb 07, 2024	424B5	Prospectus Filed
Feb 06, 2024	8-K	Current Report
Feb 05, 2024	8-K	Current Report
Feb 05, 2024	424B5	Prospectus Filed

Peers (Alternatives to Immix Biopharma, Inc. Common Stock)

Name	Mkt Capsorted ascending	Revenue	Price %, 1M	Returns, 1Y	P/E	P/S	Rev 1-Yr	Inc 1-Yr
LARGE-CAP
MRNA	41.2B	6.8B	2.33%	-21.90%	-8.74	6.02	-64.45%	-156.37%
HILS	22.4B	152.6K	-0.77%	465779.94%	-2.4K	146.8K	-	-9.98%
ALNY	18.4B	1.8B	-0.30%	-28.67%	-41.79	10.06	76.23%	61.08%
BMRN	17.4B	2.4B	8.14%	-4.26%	103.61	7.18	15.42%	18.43%
INCY	11.6B	3.7B	-9.39%	-31.39%	19.4	3.14	8.87%	75.42%
MID-CAP
APLS	5.9B	396.6M	-12.04%	-45.12%	-11.11	14.81	425.83%	18.94%
BBIO	4.5B	-	-13.93%	67.39%	-6.85	60.35	54.84%	-34.79%
AXSM	3.5B	270.6M	-9.40%	-0.33%	-14.47	12.79	440.80%	-27.84%
ARWR	2.9B	240.7M	-12.61%	-20.79%	-9.93	12.18	-1.03%	-92.09%
ACAD	2.8B	726.4M	-6.74%	-16.88%	-45.01	3.8	40.45%	71.62%
SMALL-CAP
CPRX	1.7B	398.2M	-6.36%	-10.84%	24.31	4.36	85.90%	-14.05%
NVAX	587.8M	983.7M	-10.64%	-48.02%	-1.08	0.6	-50.36%	17.16%
CRBP	396.0M	881.7K	8.01%	271.09%	-8.88	466.16	-77.61%	-5.33%
INO	242.4M	4.9M	-10.76%	0.48%	-1.79	49.8	-54.97%	51.71%
IBIO	6.7M	2.1M	76.15%	62.71%	-0.25	2.14	-13.45%	66.37%

Immix Biopharma, Inc. Common Stock News

Latest updates

Immix Biopharma, Inc. Common Stock Earnings Report: Key Takeaways & Analysis

Balance Sheet

(In Millions)

(*) denotes actual numbers (not divided by Millions)
Balance Sheet										(In Millions)
Description	(%) Q/Q	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2020Q4
Assets	-11.3%	20.00	22.00	16.00	13.00	15.00	17.00	19.00	20.00	18.00	-
Current Assets	-11.4%	20.00	22.00	16.00	13.00	15.00	17.00	19.00	20.00	18.00	1.00
Cash Equivalents	-10.6%	18.00	20.00	13.00	11.00	13.00	17.00	18.00	19.00	18.00	0.00
Net PPE	25.2%	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Liabilities	31.7%	4.00	3.00	2.00	1.00	2.00	1.00	1.00	0.00	0.00	5.00
Current Liabilities	31.7%	4.00	3.00	2.00	1.00	1.00	1.00	1.00	0.00	0.00	5.00
Shareholder's Equity	-17.0%	16.00	20.00	13.00	12.00	13.00	17.00	18.00	20.00	18.00	-
Retained Earnings	-10.5%	-53.41	-48.32	-44.04	-40.46	-37.99	-34.19	-32.65	-31.09	-29.76	-5.37
Additional Paid-In Capital	2.4%	70.00	68.00	57.00	52.00	51.00	51.00	51.00	51.00	48.00	1.00
Shares Outstanding	1.6%	20.00	20.00	16.00	14.00	14.00	14.00	14.00	14.00	13.00	3.00
Minority Interest	-61.8%	-0.20	-0.12	-0.06	-0.03	-	-	-	-	-	-
Float	-	-	-	28.00	-	-	-	18.00	-	-	-

Cashflow (Last 12 Months)

(In Thousands)

(*) denotes actual numbers (not divided by Thousands)
Cashflow (Quarterly)													(In Thousands)
Description	(%) Q/Q	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4
Cashflow From Operations	13.3%	-2,677	-3,086	-3,515	-2,092	-3,903	-1,462	-547	-1,494	-1,114	-50.76	-158	-266	-
Share Based Compensation	42.5%	1,051	737	448	330	230	213	116	65.00	122	62.00	31.00	4.00	-
Cashflow From Investing	-Infinity%	-13.18	-	-	-	-	-	-	-	-	-	-	-802*	-
Cashflow From Financing	-94.2%	587	10,066	4,692	119	424	-	-105	2,914	18,720	-18.35	82.00	65.00	-
Buy Backs	-	-	-	-	-	44.00	-	56.00	-	-	-	-	-	-

IMMX Income Statement

2023-12-31

Consolidated Statements of operations and Comprehensive Loss - USD ($)	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022
Operating expenses:
General and administrative expenses	$ 7,406,082	$ 4,023,170
Research and development	8,735,031	4,195,778
Total operating expenses	16,141,113	8,218,948
Loss from operations	(16,141,113)	(8,218,948)
Other income (expense):
Interest income	572,006
Interest expense		(497)
Total other income (expense), net	572,006	(497)
Loss before provision for income taxes	(15,569,107)	(8,219,445)
Provision for income taxes	26,415	10,268
Net loss	(15,595,522)	(8,229,713)
Net loss attributable to non-controlling interests	169,474
Net loss attributable to Immix Biopharma, Inc. common stockholders	(15,426,048)	(8,229,713)
Other comprehensive income (loss):
Foreign currency translation	47,645	(38,387)
Total other comprehensive income (loss)	47,645	(38,387)
Comprehensive loss	(15,378,403)	(8,268,100)
Less: comprehensive loss attributable to non-controlling interests
Comprehensive loss attributable to Immix Biopharma, Inc. common stockholders	$ (15,378,403)	$ (8,268,100)
Loss per common share - basic	$ (0.89)	$ (0.59)
Loss per common share - diluted	$ (0.89)	$ (0.59)
Weighted average shares outstanding - basic	17,341,146	13,887,309
Weighted average shares outstanding - diluted	17,341,146	13,887,309

IMMX Balance Sheet

2023-12-31

Consolidated Balance Sheets - USD ($)	Dec. 31, 2023	Dec. 31, 2022
Current assets:
Cash and cash equivalents	$ 17,509,791	$ 13,436,714
Tax receivable	1,172,183	255,705
Prepaid expenses and other current assets	1,105,776	1,205,398
Total current assets	19,787,750	14,897,817
Deferred offering costs	87,229	6,724
Equipment, net	50,181	3,560
Total assets	19,925,160	14,908,101
Current liabilities:
Accounts payable and accrued expenses	3,721,783	1,273,296
Total current liabilities	3,721,783	1,273,296
Funds held for subsidiary private offering		475,000
Total liabilities	3,721,783	1,748,296
Commitments and contingencies
Stockholders’ equity:
Preferred stock, $0.0001 par value; 10,000,000 shares authorized; no shares issued and outstanding
Common stock, $0.0001 par value; 200,000,000 shares authorized; 19,994,719 shares issued and 19,922,356 shares outstanding at December 31, 2023, and 13,964,485 shares issued and 13,892,122 shares outstanding at December 31, 2022	2,000	1,397
Additional paid-in capital	69,779,706	51,156,597
Accumulated other comprehensive income	134,666	87,021
Accumulated deficit	(53,411,295)	(37,985,247)
Treasury stock at cost, 72,363 shares as of December 31, 2023 and 2022	(99,963)	(99,963)
Total Immix Biopharma, Inc. stockholders’ equity	16,405,114	13,159,805
Non-controlling interests	(201,737)
Total stockholders’ equity	16,203,377	13,159,805
Total liabilities and stockholders’ equity	$ 19,925,160	$ 14,908,101

About Immix Biopharma, Inc. Common Stock

Immix Biopharma, Inc., a clinical-stage biopharmaceutical company, engages in developing tissue-specific therapeutics in oncology and inflammation in the United States and Australia. The company is developing IMX-110 that is in Phase 1b/2a clinical trials for the treatment of soft tissue sarcoma and solid tumors; IMX-111, a tissue-specific biologic for the treatment of colorectal cancers; and IMX-120, a tissue-specific biologic for the treatment of ulcerative colitis and severe Crohn's disease. It has a clinical collaboration and supply agreement with BeiGene Ltd. for a combination Phase 1b clinical trial in solid tumors of IMX-110 and anti-PD-1 Tislelizumab. The company was incorporated in 2012 and is headquartered in Los Angeles, California.

CEO	Dr. Ilya Rachman M.B.A., M.D., MBA, Ph.D.
WEBSITE	immixbio.com
INDUSTRY	Biotechnology
EMPLOYEES	9

Immix Biopharma, Inc. Common Stock Frequently Asked Questions

What is the ticker symbol for Immix Biopharma, Inc. Common Stock? What does IMMX stand for in stocks?

IMMX is the stock ticker symbol of Immix Biopharma, Inc. Common Stock. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of Immix Biopharma, Inc. Common Stock (IMMX)?

As of Tue Apr 23 2024, market cap of Immix Biopharma, Inc. Common Stock is 61.24 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of IMMX stock?

You can check IMMX's fair value in chart for subscribers.

What is the fair value of IMMX stock?

You can check IMMX's fair value in chart for subscribers. The fair value of Immix Biopharma, Inc. Common Stock is provided for various growth and macro-economic scenarios from very pessimiatic to very optimistic assumptions. These fair values are estimates from Grufity's Fair Value model based on company's past performance. However, past performance of Immix Biopharma, Inc. Common Stock is no guarantee of future performance. These fairvalue estimates should only be used as one of the inputs in your stock analysis. We provide model's historical fair value estimates for IMMX so that you know how good or bad the model has been in the past so you can discard it if needed. There are others that provide fair values of stocks such as wallmine, finbox, gurufocus and finviz. Most provide point in time estimates. We provide a history of our models fair value estimates so that you can get a sense of it's usefulness. Otherwise this data point is of little use.

Is Immix Biopharma, Inc. Common Stock a good stock to buy?

The fair value guage provides a quick view whether IMMX is over valued or under valued. Whether Immix Biopharma, Inc. Common Stock is cheap or expensive depends on the assumptions which impact Immix Biopharma, Inc. Common Stock's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for IMMX.